Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events.
Langton
Paul E
PE
Hankey
Graeme J
GJ
Eikelboom
John W
JW
D002318:Cardiovascular Diseases / Q000139:chemically induced*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D011358:Product Surveillance, Postmarketing; D018570:Risk Assessment; D013450:Sulfones / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib